Age-related macular degeneration (AMD) is a demon of the elderly, snatching away their sight at a time in life when, for many, to watch the world is one of the great pleasures - a pleasure not afforded them in the busy, earlier years.

If the drug doesn't work as a monotherapy, then give up and try to find someone else who wants to take over development. Such was the eminently practical approach taken last week by Amgen Inc. with regard to epratuzumab, also known as LymphoCide, for non-Hodgkin's lymphoma partnered with Immunomedics Inc. in North America and Australia. (BioWorld Financial Watch)